Preclinical studies testing combinations of PI3K/AKT/mTOR and MEK/ERK pathway-directed inhibitors have shown impressive anti-tumor effects in a variety of cancer subtypes, but these drug combinations have proven toxic in humans [24, 25]. This evidence concerns the gene AKT1 and cancer.